Preventing Cytomegalovirus Disease in Lung Transplant Recipients
Prophylaxis Guided by Cytomegalovirus-specific T Cell Immunity to Prevent Cytomegalovirus Disease in Lung Transplant Recipients: a Single Center Prospective Study
University of Miami · NCT06494033
This study looks at how lung transplant patients' immune systems respond to Cytomegalovirus to see if it can help prevent disease after their transplant.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | University of Miami (other) |
| Locations | 1 site (Miami, Florida) |
| Trial ID | NCT06494033 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the clinical outcomes related to Cytomegalovirus (CMV) in lung transplant recipients by monitoring their immunological responses to the virus. Participants will be followed to assess how their immune systems respond to CMV, particularly focusing on those with positive CMV IgG. The study will involve lung transplant candidates who are expected to undergo either single or double lung transplants.
Who should consider this trial
Good fit: Ideal candidates for this study are adult lung transplant candidates over 18 years of age with a positive CMV IgG.
Not a fit: Patients who are HIV infected, pregnant or breastfeeding, or those with negative CMV IgG prior to transplant will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly reduce the incidence of CMV disease in lung transplant recipients, improving their overall health outcomes.
How similar studies have performed: While this approach is focused on CMV-specific T cell immunity, similar studies have shown promise in managing viral infections in transplant populations, suggesting potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adult patients over 18 years of age 2. Lung transplant candidates with positive CMV IgG 3. Anticipated to receive a lung transplant (both double lung and single lung) Exclusion Criteria: 1. Negative CMV IgG prior transplant 2. Pregnant or breastfeeding women 3. HIV infected patients 4. Combined organ (e.g., lung-heart, lung-kidney) transplant candidates
Where this trial is running
Miami, Florida
- University of Miami — Miami, Florida, United States (RECRUITING)
Study contacts
- Principal investigator: Yoichiro Natori, MD — University of Miami
- Study coordinator: Yoichiro Natori, MD
- Email: yxn138@med.miami.edu
- Phone: 3053556323
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lung Diseases